Clinical and biologic characteristics in the 2 study groups at enrollment
| Characteristic . | Study group . | |
|---|---|---|
| FAMP (n = 46) . | CAP (n = 46) . | |
| Median age (range), y | 64 (34.6-74) | 64.7 (39.5-75) |
| Sex (M/F) | 34/12 | 28/18 |
| No. of patients with tumors | 27 | 31 |
| Mean (range) no. of mo between diagnosis and enrollment | 44.6 (5.3-207.9) | 58.9 (3.15-220) |
| Mean (range) no. of mo between end of first-line treatment and enrollment | 2.7 (1.4-13.7) | 3 (0.6-57.2) |
| No. of patients with first relapse | 26 | 24 |
| No. of patients with resistant disease | 20 | 22 |
| Mean (range) IgM, g/L | 36.3 (8.4-46) | 28.9 (10-73.7) |
| Mean (range) hemoglobin level, g/L | 107 (50-149) | 94 (63-144)* |
| Mean (range) platelet count, × 109/L | 188 (9-429) | 155 (5-460) |
| Mean (range) lactate dehydrogenase level, U/L | 272 (79-1950) | 242 (95-1725) |
| Mean (range) C-reactive protein level, mg/L | 19.2 (2-122) | 18.5 (2-108)* |
| Mean (range) β2 microglobulin level, mg/L | 2.58 (1.6-13) | 3.1 (1.4-9.3) |
| Characteristic . | Study group . | |
|---|---|---|
| FAMP (n = 46) . | CAP (n = 46) . | |
| Median age (range), y | 64 (34.6-74) | 64.7 (39.5-75) |
| Sex (M/F) | 34/12 | 28/18 |
| No. of patients with tumors | 27 | 31 |
| Mean (range) no. of mo between diagnosis and enrollment | 44.6 (5.3-207.9) | 58.9 (3.15-220) |
| Mean (range) no. of mo between end of first-line treatment and enrollment | 2.7 (1.4-13.7) | 3 (0.6-57.2) |
| No. of patients with first relapse | 26 | 24 |
| No. of patients with resistant disease | 20 | 22 |
| Mean (range) IgM, g/L | 36.3 (8.4-46) | 28.9 (10-73.7) |
| Mean (range) hemoglobin level, g/L | 107 (50-149) | 94 (63-144)* |
| Mean (range) platelet count, × 109/L | 188 (9-429) | 155 (5-460) |
| Mean (range) lactate dehydrogenase level, U/L | 272 (79-1950) | 242 (95-1725) |
| Mean (range) C-reactive protein level, mg/L | 19.2 (2-122) | 18.5 (2-108)* |
| Mean (range) β2 microglobulin level, mg/L | 2.58 (1.6-13) | 3.1 (1.4-9.3) |
FAMP indicates fludarabine; CAP, cyclophosphamide, doxorubicin, and prednisone.
Significant difference between the 2 groups.